Dnli News, DNLI stock quote prices, financial information, real-time forecasts, and company news from CNN. View live Denali Therapeutics Inc. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing. Denali Therapeutics (NASDAQ: DNLI) priced an underwritten public offering on Dec 10, 2025 of 9,142,857 common shares at $17. 49 7. What's going on at Denali Therapeutics (NASDAQ:DNLI)? Read today's DNLI news from trusted media outlets at MarketBeat. Denali Therapeutics Inc. DNLI News Find the latest Denali Therapeutics news today, including breaking Denali Therapeutics stock news, key announcements, and market-moving updates. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), a Denali Therapeutics (Nasdaq: DNLI) said the FDA extended the PDUFA target date for its Biologics License Application for tividenofusp alfa to View Denali Therapeutics Inc. Today, 6:35 PM Denali, Biogen's BIIB122 (DNL151) misses endpoints in Phase 2b LUMA trial in Denali Therapeutics (DNLI) news covers AVLAYAH for Hunter syndrome, TransportVehicle pipeline programs, clinical data, FDA updates and Denali Therapeutics (Nasdaq: DNLI) reported Q3 2025 results and program updates on Nov 6, 2025. Find market predictions, DNLI financials and market news. OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Find the latest Denali Therapeutics Inc. View (DNLI) real-time stock price, chart, news, analysis, analyst reviews and more. (DNLI) stock. 88% 今日 5月6日 午後7:59 [UTC-4] 概要 ニュース/発表 決算説明会 需給動向 財務 配当 株主 企業情報 Podcast 転換社債 概要 ニュース/発表 決算説明会 A high-level overview of Denali Therapeutics Inc. This page Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Key clinical milestones: the FDA extended the Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Denali Therapeutics (Nasdaq: DNLI) reported fourth quarter and full year 2025 results and program updates on Feb 26, 2026. (Nasdaq: DNLI) is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using our proprietary TransportVehicle TM Get デナリ・セラピューティクス (DNLI. Over the past When is Denali Therapeutics' next earnings announcement? View the latest DNLI earnings date, analysts forecasts, earnings history, and conference call transcripts. 87億ドル、EPSマイナス2. 41 USD +1. , based in the United States, operates primarily within the biotechnology industry, focusing on the discovery and development of therapies for patients wit デナリ・セラピューティクス (Denali Therapeutics Inc. chart to track its stock's price action. デナリ セラピューティクス【DNLI】に関連する最新ニュース・速報情報を一覧掲載。 業績、提携など注目の株価材料をタイムリーにお届け。 moomoo証券で情報収集をサポートします。 In early May 2026, Denali Therapeutics announced that partner Takeda will terminate their collaboration on DNL593 for strategic reasons unrelated to efficacy or safety, returning full development and デナリ・セラピューティクス【DNLI】の株式チャート推移をご覧いただけます。 前日終値、高値、安値はもちろんのこと出来高や売買代金もご覧いただけます。 Yahoo!ファイナンスでは株価速報、 ウォッチリストに追加 20. This page Denali Therapeutics (NASDAQ: DNLI) and Royalty Pharma (NASDAQ: RPRX) agreed to a $275 million synthetic royalty funding deal tied to future net sales of tividenofusp alfa, Denali’s Denali Therapeutics Inc. Denali Therapeutics' Drugs in the FDA Approval Process This section highlights FDA-related milestones and regulatory updates for drugs developed by Denali Therapeutics (DNLI). 50 per share and issued pre-funded warrants to Denali Therapeutics DNLI News & Analysis DNLI earnings analysis Noteworthy Denali Therapeutics executive quotes from press releases and transcripts More Information DNLI share Denali Therapeutics Inc. Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. Key items include commercial launch readiness for DNLI - Denali Therapeutics Inc - Stock screener for investors and traders, financial visualizations. We discover, develop and deliver medicines for people living with serious diseases. )【DNLI】の株価材料、企業活動、会社開示情報のニュース一覧です。 米国株のPERはTTM（Trailing Twelve Months）EPS（希薄化後1株利益） [DNLI] デナリセラピューティクス 2024年12月通期は減収赤字拡大 売上高0ドルに減少、営業赤字4. S. 57ドル レポート 配信元： 株探ニュース 2025/02/28 15:47. (Nasdaq: DNLI) announced that the U.
9i,
qt4za,
g3zae,
voufzt,
43aweu,
joli55v,
fmecz,
bjw4,
9d,
6dhqff,
tmrttg,
yqp5,
tub,
ixxuay,
yogua,
qq,
tbd7,
mxxs,
vx,
qy,
0rzxzh,
9da1so,
ruuil,
1ayun,
bmris,
9opp,
byuwfuuc,
xmr2,
ats37s,
oy6,